Call for abstracts opens January 20, 2021.
The deadline to submit an abstract is March 22, 2021 9 a.m. EST.

The MSK 2021 Scientific Program Committee invites abstract submissions focusing on musculoskeletal approaches in bleeding disorders.

Submission of an abstract acknowledges your consent to the following.

  • If accepted, your abstract may be published in Haemophilia, the official journal of the WFH
  • If accepted as an oral presentation, your presentation may be posted on the WFH website and post conference
  • If accepted as a poster presentation, your poster will be displayed in the virtual poster gallery

The deadline for abstract submission is March 22, 2021 at 9 a.m. EST. The results of the peer review will be announced on the week of April 5, 2021. The submitter will be notified by email.

Presenting authors (for both orals and posters) must register to attend MSK 2021. If the presenting author is not registered by April 15, 2021, the abstract will not be included in the final program.

During the abstract submission process, you will be asked to enter author information and affiliations. Please make sure that you include the full list of authors in your preferred citation order.

If an author or immediate family member has had a substantial personal financial relationship relating to the support of the abstract, this relationship must be disclosed. Such relationships include salaries, ownerships, equity positions, stock options, royalties, consulting fees and honoraria for speaking, material support or other financial arrangements. During the abstract submission process, you will be asked to disclose any potential conflicts of interest.

Your abstract must be submitted in English.

Each author may present a maximum of two abstracts during the Congress. The number of submissions is unlimited. Should an author have more than two abstracts accepted, a co-author must be named as presenting author for the additional abstracts.

Encore submissions are acceptable, but must be indicated as such when submitting the abstract. Please note that encore presentations will be accepted as e-poster presentations only.

Abstracts should be no more than 350 words in length; the title is not included in the word count.

Abstracts are to be submitted through our online submission system. Please fill in the sections indicated within the online submission form.

During the abstract submission, you will be asked your preferred presentation format:

  • Free paper (oral presentation)
  • ePoster presentation

Authors selecting free paper may be offered an ePoster presentation if not selected for an oral.

  • Challenges of hemophilia and musculoskeletal issues during COVID19
  • Clinical assessment
  • Clinical cases
  • Imaging
  • Orthopedic issues
  • Patient reported outcomes
  • Pain management
  • Physical therapy
  • Rehabilitation
  • Risk management
  • Scoring systems
  • Replacement surgery
  • Rheumatology
  • Sport/fitness/Physical activity
  • Surgical treatment
  • Synovitis
  • Telehealth

Presenters of any free papers selected for inclusion in the Musculoskeletal Congress are eligible for the Henri Horoszowski Award.

Presentations are judged on scientific methodology, originality, relevance and quality of the presentation by a panel of judges appointed by the MSK executive.

The winner will be announced at the MSK committee’s Annual General Assembly on Friday, May 7, 2021.

Abstracts that are accepted will be presented in one of the two formats below.

Oral presentation
The free paper presentations will be scheduled during the MSK Congress from May 3 to 7, 2021. Presenting authors will be notified about their presentation time once the abstract is accepted as a free paper. Oral presentations are 10 minutes in length, and will be followed by a 5-minute period for questions and answers. Presenting authors will be reviewed during their presentation, and the Henri Horoszowski Award recipient will be announced on the final day of the Congress.

ePoster presentation
ePosters will be available for viewing during the week of May 3 on our electronic poster platform, and will remain online for one month after the event. Virtual poster guidelines and information on how to submit will be included in the abstract notification email.

Questions?

Please email your questions to for further support.

The 17th WFH International MSK Congress is supported by funding from:

 

Gold sponsor

Silver sponsor

 

     View Sample Abstract   

     Submit Here   

Sample Abstract


Abstracts should be no more than 350 words in length; Predictors of response to combination therapy with recombinant factor VIIa and factor VIII in patients with hemophilia A and high titer inhibitors

Introduction and Objectives: Although the use of bypassing agents has significantly improved the treatment of hemophilia A patients who develop inhibitors, some patients, for unknown reasons, have a poor hemostatic response to bypass therapy. Improved treatment options for patients with inhibitors are needed. Studies from our laboratory and others have shown that even small amount of factor VIII (fVIII) activity can vastly improve the thrombin generation (TG) capability of recombinant factor VIIa (fVIIa) in patients with hemophilia A and inhibitors. Materials and Methods: Plasma from patients with congenital hemophilia A and high titer inhibitors was available from our IRB approved inhibitor bank. Each plasma sample was evaluated for response to 2 U/ml fVIII (~100 U/kg dosing) with and without 2.25 mcg/ml rfVIIa in a thrombin generation assay. Residual fVIII activity at 15 minutes after addition of 2 U/ml fVIII was measured using a one-stage coagulation assay. Results: 15 different patients with inhibitor titers ranging from 5.2-109 BU/ml were tested. In the 10 patients with inhibitor titers of 5.2-28 BU/ml only 1 patient with a titer of 20 BU/ml did not respond to fVIII supplementation. In the 5 patients with inhibitor titers >42 BU/ml, there was no increase in TG. A second specimen was available for 4 patients. All 3 patients who had increased TG in the presence of fVIII continued to have increased TG in the second specimen despite up to a 2-fold difference in inhibitor titer. A subset of 10 patients also had residual fVIII activity testing. In this group residual fVIII activity strongly correlated with peak TG (r2 = 0.86, p>0.001) and also correlated with ETP (r2 = 0.54, p=0.04). Conclusions:> The majority of patients with hemophilia A and high titer inhibitors have improved TG with combined use of fVIII and rfVIIa over rfVIIa alone. Residual fVIII activity at 15 minutes was a predictor of both peak thrombin generation and ETP. An inhibitor titer above 42 BU/ml was associated with no response.